MERCODIA GLUCAGON ELISAS

BIBLIOGRAPHY
Glucagon ELISA (article no. 10-1271-01)

2018


Basu, A. et al. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. Diabetes, Obes. Metab. 20, 1615–1622 (2018).


Burke, S. J. et al. db/db Mice Exhibit Features of Human Type 2 Diabetes that are Not Present in Weight matched C57BL/6J. J. Diabetes Res. 2017, 1–36 (2017).


2015


2014


**Glucagon ELISA–10 µL (article no. 10-1281-01)**

2018


Ikeda, Y. et al. Glucagon and/or IGF-1 Production Regulates Resetting of the Liver Circadian Clock in Response to a Protein or Amino Acid-only Diet. EBioMedicine 28, 210–224 (2018).


2017


Möllmann, J. et al. The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. Diabetes, Obes. Metab. 19, 496–508 (2017).


2016


2015


2014


Mercodia AB is a Swedish biotech company focusing on the development of immunoassays for research within the field of metabolic disorders. Our assays are applicable to both animal and human models and are used for research ranging from basic scientific studies to large pre-clinical and clinical phase trials.

The company was founded in 1991 and is today a world-leading supplier of products to all major international markets.

More than ninety percent of our production is exported from our facilities in Uppsala to approximately 100 different countries around the world.

Mercodia provides a professional scientific support system by collaborating with customers and institutions worldwide to develop novel applications for existing products and unique diagnostics for emerging markets.

WHEN ACCURACY MATTERS
www.mercodia.com